Shattuck Labs, Inc. SEC Filings

Shattuck Labs insider Stephen Stout, the company's General Counsel and Corporate Secretary, acquired 12,805 shares of common stock and accompanying warrants in a private placement that closed on August 25, 2025. The combined price per share and warrant was $0.8677. The warrants allow purchase of up to 12,805 additional shares at an exercise price of $1.0846 and are exercisable from issuance until 30 days after the company publicly announces certain Phase 1 clinical trial data and the design of planned Phase 2 trial(s). Following the transaction, Stout beneficially owns 86,275 shares of common stock.

Shattuck Labs CFO Andrew R. Neill purchased 64,027 shares and received 64,027 accompanying warrants in a private placement that closed on August 25, 2025. The combined price paid for each share plus warrant was $0.8677, and the warrants have an exercise price of $1.0846. After the transaction the reporting person beneficially owned 237,473 shares. The warrants are exercisable any time after issuance until 30 days following public disclosure of specified Phase 1 clinical trial data and the planned Phase 2 design for SL-325.

Insider purchase reported: Clay B. Siegall, a director of Shattuck Labs, Inc. (STTK), participated in a private placement that closed on August 25, 2025, acquiring 128,054 shares of common stock and accompanying warrants to buy up to 128,054 additional shares. The combined price for one share plus its accompanying warrant was $0.8677. The warrants have an exercise price of $1.0846 and are exercisable from issuance until 30 days after the company publicly announces certain Phase 1 SL-325 trial data and the planned Phase 2 design.

Insider purchase and warrant grant reported for Shattuck Labs (STTK). Taylor Schreiber, the company’s Chief Executive Officer and a director, participated in a private placement that closed on August 25, 2025, acquiring 25,610 shares of common stock at $0.8677 per share and receiving accompanying warrants to buy up to 25,610 shares. After the transaction Schreiber directly owns 96,612 shares. Schreiber also holds an indirect interest of 2,610,750 shares through Houghton Capital Holdings, LLC. The warrants are exercisable until the 30th day after the issuer publicly announces specific Phase 1 clinical trial data and planned Phase 2 design.

Shattuck Labs insider purchase reported. The company's Chief Technical Officer, Abhinav A. Shukla, acquired 5,122 shares of common stock and accompanying warrants in a private placement that closed on August 25, 2025 at a combined purchase price of $0.8677 per share with accompanying warrant. The filing also notes Shukla beneficially owns 81,258 shares after the transaction, which includes 600 shares purchased via the 2020 Employee Stock Purchase Plan on February 15, 2025 and 2,000 shares under the ESPP on August 15, 2025. The warrants cover 5,122 shares exercisable upon public disclosure of Phase 1 clinical trial data and planned Phase 2 design.

Redmile Group and affiliated funds acquired warrants and pre-funded warrants in Shattuck Labs' private placement (PIPE) closed August 25, 2025, increasing their reported economic exposure to 6,379,095 shares of common stock, representing 9.99% of the outstanding class on the stated calculation basis.

The Redmile Funds paid approximately $3,555,190 in aggregate to purchase Pre-Funded Warrants and Common Warrants at a combined purchase price of $0.8676, with RBI II contributing approximately $1,777,211. The filing details registration rights for resale of Common Stock issuable on exercise and describes a Beneficial Ownership Blocker that limits actual exercises to prevent ownership above 9.99%.

Redmile Group, LLC and Jeremy Green reported acquisitions of equity-linked securities of Shattuck Labs, Inc. (STTK) in a private placement closing on August 25, 2025. Institutional investors managed by Redmile received 4,097,730 pre-funded warrants and 4,097,730 common warrants tied to the same number of common shares at a combined purchase price of $0.8676 for each paired unit. The pre-funded warrants are exercisable immediately, carry a 9.99% beneficial ownership blocker and have no expiration; the accompanying common warrants expire 30 days after a public announcement of Phase 1 clinical data and Phase 2 design. Redmile and Jeremy Green disclaim beneficial ownership except to the extent of pecuniary interest. Michael Lee resigned from the issuer’s board effective the Closing Date.

Shattuck Labs, Inc. (STTK) filed a Form 8-K reporting board-related governance updates. The filing notes a Non-Employee Director Compensation Policy and states that Dr. Baker and Dr. Ashiya intend to enter the company’s standard form of indemnification agreement. The agreement for Dr. Ashiya will be modified to reflect her status as an OrbiMed Designee, as defined in the filing. The 8-K references a press release dated August 26, 2025 and also confirms that the 8-K, including the press release attached as Exhibit 99.1, will not be deemed incorporated by reference into filings under the Exchange Act or the Securities Act.